Nanosonics Ltd (Nanosonics) specializes in infection prevention. It has developed and commercialized a groundbreaking automated disinfection solution known as trophon technology, marking the first major advancement in high-level disinfection for ultrasound probes in over two decades which consists of the trophon3 device and trophon2 Plus, designed for high-level disinfection of ultrasound probes.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Nanosonics Ltd has undertaken several R&D initiatives, including the development of the next iteration of trophon technology, trophon3, and the core technology for CORIS, a new product platform associated with the cleaning of endoscopes. The company received FDA approval for the CORIS technology and plans a controlled market release followed by a broader commercial launch in FY26. The company is also focused on expanding its product portfolio by creating new technologies and products, supported by a clearly defined framework for product ideation, development, and commercialisation. The R&D unit of the company is responsible for the research, development, and commercialisation of infection control and decontamination products and related technologies. This unit plays a crucial role in managing the company's R&D activities, including engaging with customers and experts to determine the focus of R&D efforts and supporting the processes covering product ideation, development, and commercialisation.In FY2025, the company's R&D expenses stood at AUD34.6 million, which grew 5.7% YoY and as a percentage of its revenue stood at 17.4%.